ISSUE: Innovative pricing schemes appear to be beneficial from all perspectives. Patients gain access to new treatments quicker than they otherwise might, manufacturers secure early market access for products, while the financial risk to payers is mitigated. These schemes seem particularly relevant in the context of advanced therapy medicinal products, but have also proven useful with other technology classes, such as antimicrobials and implantable medical devices.

If this is the case, why are there so few examples of successful implementation of these schemes? Is it too difficult to align the perspectives of all the stakeholders? Are the needs for data collection too burdensome? Are there administrative and legal obstacles that are difficult to overcome?

This panel will debate practical barriers and enablers of innovative pricing schemes from different stakeholder perspectives, to ultimately outline ways in which innovative pricing schemes can be successfully implemented to ensure affordability, innovation and patient access.

OVERVIEW: Oriana Ciani will moderate and introduce the panel by reporting on the findings of a recent systematic categorization of innovative pricing schemes conducted as part of the HI-PRIX project (10 mins).

Berdud will describe the results of a multi-stakeholder investigation of the costs and benefits of innovative payment model participation, with a focus on incentives and barriers for industry (10 mins).

Sampietro-Colom will draw on her experience of conducting HTA from a health care provider perspective to discuss the practicalities of designing payment schemes (10 mins).

Hivert will discuss the pros and cons of participating in innovative pricing schemes from the perspective of patients with rare diseases, where treatment options are often limited and expensive (10 mins).

The panel will then invite feedback from the audience about challenges experienced in practice, and debate around implementation strategies that could sustain instead successful adoption of such schemes in the real life (15 mins).